Pulmonx Corp (LUNG)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $2.52
- As of
Kresmion compiles this page from LUNG's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pulmonx Corp (LUNG): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full LUNG dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LUNG on one page. Preview it with sample data, then open it live with a free account.
Preview the LUNG dossierActive events for LUNG
- high13F: funds added
4 tracked funds increased LUNG this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +964% to LUNG (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +205% to LUNG (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +659% to LUNG (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +610% to LUNG (2026Q2)
FREE, NO ACCOUNT
Every event on LUNG, as it fires
You are seeing 5 of 8 events recorded on LUNG since 2026-05-29.
The five above landed across 2 days. The other 3 were recorded on 2 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LUNG (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 745848101 · 2026Q2 | $553K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 745848101 · 2026Q2 | $426K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 745848101 · 2026Q2 | $272K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 745848101 · 2026Q2 | $186K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 745848101 · 2026Q2 | $113K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LUNG
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LUNG against its peers
LUNG's operating margin of -59.3% ranks in the 41st percentile of 22 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-02-28.
| Metric | LUNG | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 90.5M USD | 32.8M USD | 76 | 22 |
| Gross margin | 74.2% | 49.1% | 87 | 18 |
| Operating margin | -59.3% | -45.7% | 41 | 22 |
| Net margin | -59.7% | -57.4% | 50 | 22 |
| Return on equity | -99.8% | -77.1% | 43 | 19 |
Peers (23): EBRCZ, SERA, LUCD, HYPR, OM, ZOMDF, LNSR, APYX, ECOR, MDNC, OWLT, POSC, QTRX, COCH, MDAI, SRTS, MYO, TELA, XTNT, SNWV, STIM, RPID, CATX. Left out: RTGN (no annual filing), TLTFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-02-28. Every figure is one full fiscal year read from one annual filing (LUNG: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LUNG on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LUNG for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.